# Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

> **NCT02145637** · PHASE1 · COMPLETED · sponsor: **Yonsei University** · enrollment: 30 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Afatinib plus Ruxolitinib combination therapy

## Key facts

- **NCT ID:** NCT02145637
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2017-11-09
- **Final completion:** 2017-11-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145637, "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02145637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*